ENTX

Entera Bio Ltd.

Price Chart

Latest Quote

$1.21

+0.01 (+0.83%)

Current Price

Previous Close	$1.20
Open	$1.20
Day High	$1.22
Day Low	$1.17
Volume	51,008

Fetched: 2026-06-22T09:15:22

Stock Information

Shares Outstanding	49.29M
Total Debt	$448K
Cash Equivalents	$4.14M
Net Income	$-12.38M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$59.64M
EPS (TTM)	$-0.26
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$55.87M
Income	$-12.38M
Book/sh	$0.23
Cash/sh	$0.08
Employees	20

Financial Ratios

Quick Ratio	2.62
Current Ratio	7.93
Debt/Eq	4.19

Returns & Margins

ROA	-45.01%
ROE	-82.33%

Ownership

Insider Ownership	23.10%
Institutional Ownership	15.98%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.20
P/B	5.28

Analyst Data

Recommendation	none
Target Price	$9.00

Technical Indicators

SMA20	$1.22
SMA50	$1.21
SMA200	$1.70
RSI	33.33
ATR	0.0654

Shares Float	40.36M
Short Float	0.42%
Short Ratio	1.69
Volatility	1.49
Rel Volume	0.78

Performance History

Week	+4.31%
Month	-4.72%
Quarter	+1.68%
6 Months	-42.11%
YTD	-31.64%
Year	-42.11%
3 Years	+45.96%
5 Years	-68.16%
10 Years	-80.73%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$1.21	51,000
2026-06-17	$1.20	29,400
2026-06-16	$1.18	88,000
2026-06-15	$1.21	86,100
2026-06-12	$1.23	45,800
2026-06-11	$1.16	25,600
2026-06-10	$1.17	16,600
2026-06-09	$1.22	24,800
2026-06-08	$1.20	26,600
2026-06-05	$1.18	60,300
2026-06-04	$1.22	53,300
2026-06-03	$1.22	44,200
2026-06-02	$1.25	132,000
2026-06-01	$1.27	104,700
2026-05-29	$1.35	166,800
2026-05-28	$1.22	75,500
2026-05-27	$1.19	189,700
2026-05-26	$1.21	29,600
2026-05-22	$1.24	26,000
2026-05-21	$1.27	38,000
2026-05-20	$1.24	23,500
2026-05-19	$1.27	30,000

About Entera Bio Ltd.

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

📰 Latest News

Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know

Zacks • 2026-04-29T16:00:05Z

Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near

MarketBeat • 2026-04-24T23:33:00Z

Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation

Insider Monkey • 2026-02-18T01:42:33Z

Opko Health (OPK) Expands Entera Partnership for Drug Co-Development

Insider Monkey • 2026-02-06T16:02:26Z

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Simply Wall St. • 2025-12-31T12:51:15Z

Individual investors are Entera Bio Ltd.'s (NASDAQ:ENTX) biggest owners and were rewarded after market cap rose by US$34m last week

Simply Wall St. • 2025-10-11T12:33:43Z

Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy

Zacks • 2025-09-18T12:41:00Z

Entera Bio Second Quarter 2025 Earnings: US$0.057 loss per share (vs US$0.058 loss in 2Q 2024)

Simply Wall St. • 2025-08-11T10:30:08Z

OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)

Insider Monkey • 2025-07-23T15:25:12Z

Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

Simply Wall St. • 2025-07-16T18:31:07Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$42,000	$172,000	$0	$101,000
Cost Of Revenue	$42,000	$172,000	$0	$101,000
Total Revenue	$42,000	$181,000	$0	$134,000
Operating Revenue	$42,000	$181,000	$0	$134,000
Expenses
Total Expenses	$11,571,000	$9,766,000	$8,891,000	$13,151,000
Net Non Operating Interest Income Expense	$90,000	$58,000	$31,000	$83,000
Total Other Finance Cost	$-90,000	$-58,000	$-31,000	$-83,000
Operating Expense	$11,529,000	$9,594,000	$8,891,000	$13,050,000
General And Administrative Expense	$5,525,000	$5,095,000	$4,430,000	$7,253,000
Other Operating Expenses	-	-	$-49,000	$-51,000
Interest Expense	-	-	-	-
Interest Expense Non Operating	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-11,439,000	$-9,541,000	$-8,889,000	$-13,071,000
Net Interest Income	$90,000	$58,000	$31,000	$83,000
Normalized Income	$-11,439,000	$-9,541,000	$-8,889,000	$-13,071,000
Net Income From Continuing And Discontinued Operation	$-11,439,000	$-9,541,000	$-8,889,000	$-13,071,000
Total Operating Income As Reported	$-11,529,000	$-9,585,000	$-8,891,000	$-13,017,000
Net Income Common Stockholders	$-11,439,000	$-9,541,000	$-8,889,000	$-13,071,000
Net Income	$-11,439,000	$-9,541,000	$-8,889,000	$-13,071,000
Net Income Including Noncontrolling Interests	$-11,439,000	$-9,541,000	$-8,889,000	$-13,071,000
Net Income Continuous Operations	$-11,439,000	$-9,541,000	$-8,889,000	$-13,071,000
Pretax Income	$-11,439,000	$-9,527,000	$-8,860,000	$-12,934,000
Operating Income	$-11,529,000	$-9,585,000	$-8,891,000	$-13,017,000
Gross Profit	$0	$9,000	$0	$33,000
Per Share
Diluted EPS	$-0.25	$-0.25	$-0.31	$-0.45
Basic EPS	$-0.25	$-0.25	$-0.31	$-0.45
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-11,499,000	$-9,539,000	$-8,835,000	$-12,953,000
Reconciled Depreciation	$30,000	$46,000	$56,000	$64,000
EBITDA (Bullshit earnings)	$-11,499,000	$-9,539,000	$-8,835,000	$-12,953,000
EBIT	$-11,529,000	$-9,585,000	$-8,891,000	$-13,017,000
Diluted Average Shares	$46,191,067	$37,650,179	$29,007,794	$28,808,090
Basic Average Shares	$46,191,067	$37,650,179	$29,007,794	$28,808,090
Diluted NI Availto Com Stockholders	$-11,439,000	$-9,541,000	$-8,889,000	$-13,071,000
Tax Provision	$0	$14,000	$29,000	$137,000
Research And Development	$6,004,000	$4,499,000	$4,510,000	$5,848,000
Selling General And Administration	$5,525,000	$5,095,000	$4,430,000	$7,253,000
Other Gand A	$5,525,000	$5,095,000	$4,430,000	$7,253,000

Fetched: 2026-06-21

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$13,101,000	$8,080,000	$10,386,000	$11,754,000
Total Assets	$15,993,000	$9,390,000	$11,765,000	$13,127,000
Total Non Current Assets	$695,000	$418,000	$508,000	$278,000
Other Non Current Assets	$90,000	$80,000	-	-
Current Assets	$15,298,000	$8,972,000	$11,257,000	$12,849,000
Other Current Assets	$415,000	$186,000	$238,000	$294,000
Restricted Cash	$7,775,000	-	-	-
Receivables	$0	$126,000	$0	$246,000
Accounts Receivable	$0	$126,000	$0	$246,000
Cash Cash Equivalents And Short Term Investments	$7,108,000	$8,660,000	$11,019,000	$12,309,000
Cash And Cash Equivalents	$7,108,000	$8,660,000	$11,019,000	$12,309,000
Non Current Deferred Assets	-	$0	$14,000	$43,000
Non Current Deferred Taxes Assets	-	$0	$14,000	$43,000
Debt
Total Debt	$490,000	$272,000	$390,000	$91,000
Long Term Debt And Capital Lease Obligation	$260,000	$102,000	$256,000	$0
Current Debt And Capital Lease Obligation	$230,000	$170,000	$134,000	$91,000
Liabilities
Total Liabilities Net Minority Interest	$2,892,000	$1,310,000	$1,379,000	$1,373,000
Total Non Current Liabilities Net Minority Interest	$689,000	$134,000	$288,000	$32,000
Other Non Current Liabilities	$393,000	-	-	-
Current Liabilities	$2,203,000	$1,176,000	$1,091,000	$1,341,000
Payables And Accrued Expenses	$1,541,000	$667,000	$583,000	$950,000
Payables	$815,000	$132,000	$83,000	$17,000
Other Payable	$367,000	-	-	-
Accounts Payable	$448,000	$132,000	$83,000	$17,000
Current Deferred Liabilities	-	-	-	$0
Total Tax Payable	-	-	-	$0
Income Tax Payable	-	-	-	$0
Equity
Common Stock Equity	$13,101,000	$8,080,000	$10,386,000	$11,754,000
Total Equity Gross Minority Interest	$13,101,000	$8,080,000	$10,386,000	$11,754,000
Stockholders Equity	$13,101,000	$8,080,000	$10,386,000	$11,754,000
Gains Losses Not Affecting Retained Earnings	$41,000	$41,000	$41,000	$41,000
Other Equity Adjustments	$41,000	$41,000	$41,000	$41,000
Retained Earnings	$-125,366,000	$-113,927,000	$-104,386,000	$-95,497,000
Other
Ordinary Shares Number	$46,178,630	$38,837,220	$35,476,341	$28,809,922
Share Issued	$46,178,630	$38,837,220	$35,476,341	$28,809,922
Tangible Book Value	$13,101,000	$8,080,000	$10,386,000	$11,754,000
Invested Capital	$13,101,000	$8,080,000	$10,386,000	$11,754,000
Working Capital	$13,095,000	$7,796,000	$10,166,000	$11,508,000
Capital Lease Obligations	$490,000	$272,000	$390,000	$91,000
Total Capitalization	$13,101,000	$8,080,000	$10,386,000	$11,754,000
Additional Paid In Capital	$138,425,000	$121,965,000	$114,730,000	$107,210,000
Capital Stock	$1,000	$1,000	$1,000	$0
Common Stock	$1,000	$1,000	$1,000	$0
Employee Benefits	$36,000	$32,000	$32,000	$32,000
Non Current Pension And Other Postretirement Benefit Plans	$36,000	$32,000	$32,000	$32,000
Long Term Capital Lease Obligation	$260,000	$102,000	$256,000	$0
Current Capital Lease Obligation	$230,000	$170,000	$134,000	$91,000
Pensionand Other Post Retirement Benefit Plans Current	$432,000	$339,000	$374,000	$300,000
Current Accrued Expenses	$726,000	$535,000	$500,000	$933,000
Defined Pension Benefit	$6,000	$6,000	$6,000	$6,000
Net PPE	$599,000	$332,000	$488,000	$229,000
Gross PPE	$599,000	$332,000	$488,000	$229,000
Other Properties	$599,000	$332,000	$488,000	$229,000
Treasury Shares Number	-	-	$0	-
Current Deferred Revenue	-	-	-	$0

Fetched: 2026-06-21

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-7,477,000	$-6,821,000	$-7,327,000	$-12,546,000
Operating Activities
Operating Cash Flow	$-7,370,000	$-6,818,000	$-7,310,000	$-12,499,000
Cash Flow From Continuing Operating Activities	$-7,370,000	$-6,818,000	$-7,310,000	$-12,499,000
Investing Activities
Capital Expenditure	$-107,000	$-3,000	$-17,000	$-47,000
Investing Cash Flow	$-107,000	$-3,000	$-17,000	$-102,000
Cash Flow From Continuing Investing Activities	$-107,000	$-3,000	$-17,000	$-102,000
Net Other Investing Changes	-	-	-	$-55,000
Financing Activities
Issuance Of Capital Stock	$13,444,000	$3,960,000	$6,616,000	$0
Financing Cash Flow	$13,710,000	$4,476,000	$6,036,000	$13,000
Cash Flow From Continuing Financing Activities	$13,710,000	$4,476,000	$6,036,000	$13,000
Net Other Financing Charges	$-262,000	$-323,000	$-580,000	-
Net Common Stock Issuance	$13,444,000	$3,960,000	$6,616,000	$0
Common Stock Issuance	$13,444,000	$3,960,000	$6,616,000	$0
Other
End Cash Position	$14,973,000	$8,740,000	$11,085,000	$12,376,000
Beginning Cash Position	$8,740,000	$11,085,000	$12,376,000	$24,964,000
Effect Of Exchange Rate Changes	$-36,000	$0	-	-
Changes In Cash	$6,269,000	$-2,345,000	$-1,291,000	$-12,588,000
Proceeds From Stock Option Exercised	$528,000	$839,000	$0	$13,000
Net PPE Purchase And Sale	$-107,000	$-3,000	$-17,000	$-47,000
Purchase Of PPE	$-107,000	$-3,000	$-17,000	$-47,000
Change In Working Capital	$1,257,000	$112,000	$-195,000	$-1,835,000
Change In Other Current Assets	$-229,000	$-14,000	$56,000	$-40,000
Change In Payables And Accrued Expense	$1,360,000	$252,000	$-497,000	$-1,717,000
Change In Accrued Expense	$1,044,000	$203,000	$-563,000	$-1,568,000
Change In Payable	$316,000	$49,000	$66,000	$-149,000
Change In Account Payable	$316,000	$49,000	$66,000	$-149,000
Change In Receivables	$126,000	$-126,000	$246,000	$-63,000
Changes In Account Receivables	$126,000	$-126,000	$246,000	$-63,000
Other Non Cash Items	$32,000	$-5,000	-	$-78,000
Stock Based Compensation	$2,750,000	$2,556,000	$1,689,000	$2,247,000
Depreciation Amortization Depletion	$30,000	$46,000	$56,000	$64,000
Depreciation And Amortization	$30,000	$46,000	$56,000	$64,000
Depreciation	$30,000	$46,000	$56,000	$64,000
Net Income From Continuing Operations	$-11,439,000	$-9,541,000	$-8,889,000	$-13,071,000
Deferred Tax	-	$14,000	$29,000	$174,000
Deferred Income Tax	-	$14,000	$29,000	$174,000
Income Tax Paid Supplemental Data	-	-	$0	$165,000
Change In Other Working Capital	-	-	-	$-15,000

Fetched: 2026-06-21